Refine
Has Fulltext
- yes (12)
Is part of the Bibliography
- yes (12) (remove)
Year of publication
Document Type
- Journal article (12)
Language
- English (12) (remove)
Keywords
- consortium (4)
- sphingolipids (4)
- genetic modifiers (3)
- investigators (3)
- common variants (2)
- ovarian cancer (2)
- single-nucleotide polymorphisms (2)
- CD4+ T cells (1)
- CD8+ T cells (1)
- DNA (1)
Institute
- Institut für Organische Chemie (7)
- Theodor-Boveri-Institut für Biowissenschaften (5)
- Institut für Humangenetik (4)
- Institut für Virologie und Immunbiologie (4)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Institut für Geographie und Geologie (1)
- Institut für Hygiene und Mikrobiologie (1)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (1)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (1)
- Neurologische Klinik und Poliklinik (1)
EU-Project number / Contract (GA) number
- 223175 (3)
A fine balance of regulatory (T\(_{reg}\)) and conventional CD4\(^+\) T cells (T\(_{conv}\)) is required to prevent harmful immune responses, while at the same time ensuring the development of protective immunity against pathogens. As for many cellular processes, sphingolipid metabolism also crucially modulates the T\(_{reg}\)/T\(_{conv}\) balance. However, our understanding of how sphingolipid metabolism is involved in T cell biology is still evolving and a better characterization of the tools at hand is required to advance the field. Therefore, we established a reductionist liposomal membrane model system to imitate the plasma membrane of mouse T\(_{reg}\) and T\(_{conv}\) with regards to their ceramide content. We found that the capacity of membranes to incorporate externally added azide-functionalized ceramide positively correlated with the ceramide content of the liposomes. Moreover, we studied the impact of the different liposomal preparations on primary mouse splenocytes in vitro. The addition of liposomes to resting, but not activated, splenocytes maintained viability with liposomes containing high amounts of C\(_{16}\)-ceramide being most efficient. Our data thus suggest that differences in ceramide post-incorporation into T\(_{reg}\) and T\(_{conv}\) reflect differences in the ceramide content of cellular membranes.
Recently, we have shown that C6-ceramides efficiently suppress viral replication by trapping the virus in lysosomes. Here, we use antiviral assays to evaluate a synthetic ceramide derivative α-NH2-ω-N3-C6-ceramide (AKS461) and to confirm the biological activity of C6-ceramides inhibiting SARS-CoV-2. Click-labeling with a fluorophore demonstrated that AKS461 accumulates in lysosomes. Previously, it has been shown that suppression of SARS-CoV-2 replication can be cell-type specific. Thus, AKS461 inhibited SARS-CoV-2 replication in Huh-7, Vero, and Calu-3 cells up to 2.5 orders of magnitude. The results were confirmed by CoronaFISH, indicating that AKS461 acts comparable to the unmodified C6-ceramide. Thus, AKS461 serves as a tool to study ceramide-associated cellular and viral pathways, such as SARS-CoV-2 infections, and it helped to identify lysosomes as the central organelle of C6-ceramides to inhibit viral replication.